Sign In
Buy HTBX
$2.38
+0 (+0%)
At Close: Aug 17, 2022
Maxim Group Assigns a Buy Rating on Heat Biologics (HTBX) - Markets
05:31pm, Friday, 19'th Jun 2020
Maxim Group analyst Jason McCarthy assigned a Buy rating to Heat Biologics (HTBX – Research Report) today and set a
Heat Biologics Announces Initiation of the Lead Clinical Trial Site for PTX-35 | | IT Business Net
12:11pm, Thursday, 18'th Jun 2020
Anthony Tolcher, M.D., FRCPC appointed as the lead investigator DURHAM, NC / ACCESSWIRE / June 18, 2020 / Heat Biologics, Inc. ("Heat") (NASDAQ:HTBX), a clinical-stage biopharmaceutical comp
Heat Biologics Announces Initiation of the Lead Clinical Trial Site for PTX-35
11:30am, Thursday, 18'th Jun 2020
DURHAM, NC / ACCESSWIRE / June 18, 2020 / Heat Biologics, Inc. ("Heat") (HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system,
FerGene Appoints Top Biotech Leaders to Executive Team
12:00am, Wednesday, 17'th Jun 2020
FerGene, Inc., a privately held gene therapy company dedicated to revolutionizing the treatment of bladder cancer, today announced the appointment of
Viela Bio Gets Approval And Other News: The Good, Bad And Ugly Of Biopharma (NASDAQ:VIE)
09:13am, Tuesday, 16'th Jun 2020
Viela Bio receives FDA approval for Uplizna. Exelixis starts late stage lung cancer study. Agios reports positive proof of concept study.
How to buy Heat Biologics shares from Australia | 16 Jun price $0.787
02:17am, Tuesday, 16'th Jun 2020
Ever wondered how to buy shares in Heat Biologics in Australia? We explain how and compare the best share trading platforms.
Genprex Expands Manufacturing Program with Aldevron to Advance Oncoprex™ Clinical Development
12:00am, Tuesday, 16'th Jun 2020
Genprex Expands its Manufacturing Program for Lead Drug Candidate, Oncoprex
Signs That Bristol Myers Squibb Can Finally Break Cycle Of Under-Performance (NYSE:BMY)
09:57pm, Monday, 15'th Jun 2020
Bristol Myers Squibb stock has provided a poor return for investors over the past 5 years but there are signs its $76bn acquisition of Celgene has sparked a rev
NICE backs funding for Roche's lung cancer drug after price cut -
10:21am, Monday, 15'th Jun 2020
NICE has recommended NHS funding for Roche’s Rozlytrek (entrectinib) as a treatment option for advanced non-small cell lung cancer with a rare mutation in final draft guidance.
Xconomy: GlaxoSmithKline Keeps Oncology 2.0 Growth Plans on Track
03:47am, Saturday, 13'th Jun 2020
GlaxoSmithKline's years-long oncology resurgence is on track to have two new drugs approved in the US in mid-2020, after the company won a key first-line
3 “Strong Buy” Penny Stocks With Massive Upside Ahead
01:57pm, Friday, 12'th Jun 2020
Penny stocks, you either love them or you hate them. One of the obvious draws of these stocks trading for under $5 per share is the ability to get more
Creatv Announces Ability to Predict Immunotherapy Treatment Response for Non-Small Cell Lung Cancer (NSCLC) using a Simple Blood Test
Advaxis Reports Second Quarter Ended April 30, 2020 Financial Results and Provides a Business Update
12:00pm, Thursday, 11'th Jun 2020
Expanding Phase 1/2 Study of ADXS-503 in NSCLC based on sustained and durable clinical responses in first two patients from Part B combination arm with
Immutep (ASX:IMM) TACTI-002 and INSIGHT Clinical Results & Update
01:31am, Tuesday, 09'th Jun 2020
09 Jun 2020 - Immutep Limited (ASX:IMM) Executive Director and CEO Marc Voigt, Chief Scientific and Medical Officer Dr Frédéric Triebel, and Director Clinical Development and Regulatory Affairs Chri
